RU2004126093A - Комбинированная терапия для лечения мигрени, включающая применение производных противосудорожных средств и средств от мигрени - Google Patents
Комбинированная терапия для лечения мигрени, включающая применение производных противосудорожных средств и средств от мигрени Download PDFInfo
- Publication number
- RU2004126093A RU2004126093A RU2004126093/14A RU2004126093A RU2004126093A RU 2004126093 A RU2004126093 A RU 2004126093A RU 2004126093/14 A RU2004126093/14 A RU 2004126093/14A RU 2004126093 A RU2004126093 A RU 2004126093A RU 2004126093 A RU2004126093 A RU 2004126093A
- Authority
- RU
- Russia
- Prior art keywords
- migraine
- group
- topiramate
- serotonin
- blockers
- Prior art date
Links
- 208000019695 Migraine disease Diseases 0.000 title claims 15
- 238000002648 combination therapy Methods 0.000 title claims 4
- 238000000034 method Methods 0.000 claims 31
- 206010027599 migraine Diseases 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 12
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical group CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 claims 12
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 9
- 239000000935 antidepressant agent Substances 0.000 claims 9
- 229940005513 antidepressants Drugs 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 229960004394 topiramate Drugs 0.000 claims 9
- 239000002876 beta blocker Substances 0.000 claims 8
- 229940097320 beta blocking agent Drugs 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 5
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 claims 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 3
- 108090000189 Neuropeptides Proteins 0.000 claims 3
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims 3
- 125000002009 alkene group Chemical group 0.000 claims 3
- 229960002133 almotriptan Drugs 0.000 claims 3
- 229940035676 analgesics Drugs 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 239000000730 antalgic agent Substances 0.000 claims 3
- 230000001430 anti-depressive effect Effects 0.000 claims 3
- 230000003474 anti-emetic effect Effects 0.000 claims 3
- 229940125681 anticonvulsant agent Drugs 0.000 claims 3
- 239000001961 anticonvulsive agent Substances 0.000 claims 3
- 229940125683 antiemetic agent Drugs 0.000 claims 3
- 239000002111 antiemetic agent Substances 0.000 claims 3
- 229940125684 antimigraine agent Drugs 0.000 claims 3
- 239000002282 antimigraine agent Substances 0.000 claims 3
- 239000003420 antiserotonin agent Substances 0.000 claims 3
- 239000000480 calcium channel blocker Substances 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 229960002472 eletriptan Drugs 0.000 claims 3
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 claims 3
- 229960002284 frovatriptan Drugs 0.000 claims 3
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- -1 methylenedioxy group Chemical group 0.000 claims 3
- 229960005254 naratriptan Drugs 0.000 claims 3
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 claims 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229960002477 riboflavin Drugs 0.000 claims 3
- 235000019192 riboflavin Nutrition 0.000 claims 3
- 239000002151 riboflavin Substances 0.000 claims 3
- 229960000425 rizatriptan Drugs 0.000 claims 3
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 claims 3
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 3
- 229940121356 serotonin receptor antagonist Drugs 0.000 claims 3
- 229960003708 sumatriptan Drugs 0.000 claims 3
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims 3
- 229960001360 zolmitriptan Drugs 0.000 claims 3
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical group C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010054956 Phonophobia Diseases 0.000 claims 1
- 206010034960 Photophobia Diseases 0.000 claims 1
- 230000002460 anti-migrenic effect Effects 0.000 claims 1
- 229960001653 citalopram Drugs 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims 1
- 229960004255 nadolol Drugs 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical group C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical group C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35989402P | 2002-02-26 | 2002-02-26 | |
| US60/359,894 | 2002-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004126093A true RU2004126093A (ru) | 2005-04-10 |
Family
ID=27663315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004126093/14A RU2004126093A (ru) | 2002-02-26 | 2003-02-25 | Комбинированная терапия для лечения мигрени, включающая применение производных противосудорожных средств и средств от мигрени |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20030225002A1 (https=) |
| EP (1) | EP1478400A1 (https=) |
| JP (1) | JP2005518439A (https=) |
| KR (1) | KR101008326B1 (https=) |
| CN (1) | CN100352506C (https=) |
| AU (1) | AU2003213242A1 (https=) |
| BR (1) | BR0307951A (https=) |
| CA (1) | CA2419989A1 (https=) |
| HR (1) | HRP20040846A2 (https=) |
| IL (2) | IL163720A0 (https=) |
| MX (1) | MXPA04008259A (https=) |
| NO (1) | NO20043984L (https=) |
| NZ (1) | NZ534874A (https=) |
| PL (1) | PL372393A1 (https=) |
| RU (1) | RU2004126093A (https=) |
| UA (1) | UA81110C2 (https=) |
| WO (1) | WO2003072138A1 (https=) |
| ZA (1) | ZA200407729B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA023147B1 (ru) * | 2006-04-13 | 2016-04-29 | Тева Фармасьютикалс Интернешнл Гмбх | Трансдермальный пластырь для лечения мигрени |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
| CA2556424A1 (en) | 2004-02-17 | 2005-09-01 | Sepracor Inc. | Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites |
| US20060233892A1 (en) * | 2005-04-19 | 2006-10-19 | Curt Hendrix | Topiramate compositions for treatment of headache |
| US20060252745A1 (en) * | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| FR2890564B1 (fr) * | 2005-09-09 | 2007-10-19 | Servier Lab | Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent |
| EP2023894A4 (en) * | 2006-04-25 | 2010-10-20 | Applied Pharma Res | FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE |
| WO2008027557A2 (en) | 2006-08-31 | 2008-03-06 | Spherics, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| SI2124556T1 (sl) | 2006-10-09 | 2015-01-30 | Charleston Laboratories, Inc. | Farmacevtske sestave |
| US8298576B2 (en) | 2006-11-17 | 2012-10-30 | Supernus Pharmaceuticals, Inc. | Sustained-release formulations of topiramate |
| MX2009003911A (es) * | 2006-12-04 | 2009-05-28 | Supernus Pharmaceuticals Inc | Formulaciones de liberacion inmediata, mejoradas de topiramato. |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| EP3090743A1 (en) | 2008-01-09 | 2016-11-09 | Charleston Laboratories, Inc. | Pharmaceutical compositions for treating headache and eliminating nausea |
| JP5690732B2 (ja) * | 2008-09-17 | 2015-03-25 | ザ マクリーン ホスピタル コーポレーション | 群発頭痛障害を治療するための方法及びキット |
| CA2767576C (en) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CA3055170A1 (en) | 2016-03-04 | 2017-09-08 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| WO2018067330A1 (en) * | 2016-10-06 | 2018-04-12 | Baylor College Of Medicine | Photochromatic modulation with fluorescein for the treatment of photo-oculodynia and blepharospasm |
| EP3955933B1 (en) * | 2019-04-15 | 2023-11-29 | Vistagen Therapeutics, Inc. | Treatment of migraine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| IL103172A (en) * | 1991-09-19 | 1997-01-10 | Mcneilab Inc | Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol |
| US5242942A (en) * | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
| US5384327A (en) * | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
| US5998380A (en) * | 1995-10-13 | 1999-12-07 | New England Medical Center Hospitals, Inc. | Treatment of migraine |
| WO1998007447A1 (en) * | 1996-08-23 | 1998-02-26 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
| US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
| US20020015713A1 (en) * | 1996-10-24 | 2002-02-07 | Murdock Robert W. | Methods and transdermal compositions for pain relief |
| AU1930897A (en) * | 1997-03-03 | 1998-09-22 | Laboratoires Remilea | Plant extract compositions, method of preparation, and pharmaceutical comp ositions containing them |
| US5855907A (en) * | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
| US5935933A (en) * | 1997-07-16 | 1999-08-10 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating neuropathic pain |
| US5760007A (en) * | 1997-07-16 | 1998-06-02 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating neuropathic pain |
| GB9720270D0 (en) * | 1997-09-25 | 1997-11-26 | Pharmagene Lab Limited | Medicaments for the treatment of migraine |
| US6068999A (en) * | 1998-06-25 | 2000-05-30 | Hendrix; Curt | Dietary supplement for supporting cerebrovascular tone and treating migraine headaches |
| ATE279921T1 (de) * | 1999-01-19 | 2004-11-15 | Ortho Mcneil Pharm Inc | Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache |
| PL213323B1 (pl) * | 1999-08-20 | 2013-02-28 | Ortho Mcneil Pharm Inc | Kompozycja farmaceutyczna i jej zastosowanie |
-
2003
- 2003-02-25 RU RU2004126093/14A patent/RU2004126093A/ru not_active Application Discontinuation
- 2003-02-25 UA UA20040807114A patent/UA81110C2/uk unknown
- 2003-02-25 CN CNB038091135A patent/CN100352506C/zh not_active Expired - Lifetime
- 2003-02-25 IL IL16372003A patent/IL163720A0/xx unknown
- 2003-02-25 HR HR20040846A patent/HRP20040846A2/hr not_active Application Discontinuation
- 2003-02-25 US US10/373,488 patent/US20030225002A1/en not_active Abandoned
- 2003-02-25 NZ NZ534874A patent/NZ534874A/en not_active IP Right Cessation
- 2003-02-25 KR KR1020047013261A patent/KR101008326B1/ko not_active Expired - Fee Related
- 2003-02-25 BR BR0307951-1A patent/BR0307951A/pt not_active Application Discontinuation
- 2003-02-25 MX MXPA04008259A patent/MXPA04008259A/es unknown
- 2003-02-25 WO PCT/US2003/005463 patent/WO2003072138A1/en not_active Ceased
- 2003-02-25 JP JP2003570882A patent/JP2005518439A/ja active Pending
- 2003-02-25 PL PL03372393A patent/PL372393A1/xx not_active Application Discontinuation
- 2003-02-25 AU AU2003213242A patent/AU2003213242A1/en not_active Abandoned
- 2003-02-25 EP EP03709289A patent/EP1478400A1/en not_active Withdrawn
- 2003-02-26 CA CA002419989A patent/CA2419989A1/en not_active Abandoned
-
2004
- 2004-08-24 IL IL163720A patent/IL163720A/en active IP Right Grant
- 2004-09-23 ZA ZA200407729A patent/ZA200407729B/en unknown
- 2004-09-23 NO NO20043984A patent/NO20043984L/no unknown
-
2006
- 2006-12-08 US US11/608,276 patent/US20070099849A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA023147B1 (ru) * | 2006-04-13 | 2016-04-29 | Тева Фармасьютикалс Интернешнл Гмбх | Трансдермальный пластырь для лечения мигрени |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1478400A1 (en) | 2004-11-24 |
| PL372393A1 (en) | 2005-07-25 |
| JP2005518439A (ja) | 2005-06-23 |
| CN100352506C (zh) | 2007-12-05 |
| IL163720A (en) | 2012-06-28 |
| NZ534874A (en) | 2007-03-30 |
| NO20043984L (no) | 2004-09-23 |
| KR20040091074A (ko) | 2004-10-27 |
| MXPA04008259A (es) | 2005-05-27 |
| US20030225002A1 (en) | 2003-12-04 |
| UA81110C2 (en) | 2007-12-10 |
| BR0307951A (pt) | 2004-12-21 |
| HRP20040846A2 (en) | 2005-06-30 |
| ZA200407729B (en) | 2006-06-28 |
| IL163720A0 (en) | 2005-12-18 |
| CA2419989A1 (en) | 2003-08-05 |
| AU2003213242A1 (en) | 2003-09-09 |
| CN1646168A (zh) | 2005-07-27 |
| US20070099849A1 (en) | 2007-05-03 |
| KR101008326B1 (ko) | 2011-01-13 |
| WO2003072138A1 (en) | 2003-09-04 |
| HK1080731A1 (en) | 2006-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004126093A (ru) | Комбинированная терапия для лечения мигрени, включающая применение производных противосудорожных средств и средств от мигрени | |
| JP2005518439A5 (https=) | ||
| RU2003101430A (ru) | Препарат и способ лечения болей | |
| ES2558701T3 (es) | Tratamientos potenciados de la migraña basados en miméticos de grelina | |
| RU2363458C2 (ru) | Комбинированная лекарственная терапия для лечения ожирения | |
| CO4950530A1 (es) | Agonistas de receptores 5-ht, y metoclopramida para el tratamiento de la migrana | |
| CR7510A (es) | DERIVADOS DE [1-4] DIAZEPINO[6,7,1-iJ)] QUINOLONA COMO AGENTES ANTIPSICOTICOS Y CONTRA LA OBESIDAD | |
| AR035158A1 (es) | Inhibidores de recaptacion de norepinefrina altamente selectivos y metodo para usar los mismos | |
| RU94045897A (ru) | Производные индола в качестве 5-hti-агонистов, фармацевтическая композиция и способ лечения | |
| NO2012015I1 (no) | Dapoxetine i en hver form beskyttet av basis patent nr 330562 | |
| PE20010541A1 (es) | Uso de una composicion de benzimidazol para tratar el cancer | |
| RU2006143332A (ru) | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ | |
| CN1652758A (zh) | 使用文拉法辛和衍生物治疗胃肠和泌尿生殖疼痛症的方法 | |
| JP2005503382A5 (https=) | ||
| JP2009502931A5 (https=) | ||
| RU94045271A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера | |
| AU684313B2 (en) | Melatonin derivatives for use in treating sleep disorders | |
| JP5371762B2 (ja) | ムスカリン性受容体ｍ１拮抗薬による肥満の処置 | |
| AR029666A1 (es) | Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina | |
| WO2002024661A3 (en) | New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors | |
| RU2007126638A (ru) | Профилактическое или терапевтическое средство для лечения расстройства сна | |
| JP2002525327A5 (https=) | ||
| KR890012641A (ko) | 리실 옥시다제의 억제제 | |
| AR030552A1 (es) | Derivados del 2-aminoindano, un proceso para su preparacion, compuestos intermediarios para la preparacion de dichos derivados y el uso de los derivados para la manufactura de un medicamento | |
| RU2455981C2 (ru) | Лечение ожирения антагонистами мускаринового рецептора м1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080303 |